REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1680071
This article is part of the Research TopicThe prospects of RNA-based therapy for cancerView all articles
Incorporating mRNA Therapeutics into Biological Treatments of Hematologic Malignancies
Provisionally accepted
- 1Laboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, Poland
- 2Doctoral School, Medical University of Warsaw, Warsaw, Poland
- 3Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
- 4Department of Immunology, Medical University of Warsaw, Warsaw, Poland
- 5School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- 6International Hematology/Oncology of Pediatric Experts (IHOPE), Universal Scientific Education and Research Network, Tehran, Iran
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The recent advancement of mRNA technology has opened new therapeutic avenues for treating hematologic malignancies, offering innovative approaches to enhance existing immunotherapies. This review examines the expanding role of in vitro transcribed (IVT)-mRNA-based platforms in hemato-oncology, focusing on key areas: monoclonal antibody production, bispecific antibody development, and CAR-T cell engineering. Unlike conventional biologics, mRNA allows for in vivo expression of therapeutic proteins, reducing manufacturing complexity and expanding access through scalable, cell-free synthesis. IVT-mRNA-encoded monoclonal and bispecific antibodies can overcome limitations such as short half-life and the need for continuous infusion, while enabling innovations like Fc silencing, protease-activated masking, and combinatorial immunotherapies. In CART cell therapy, IVT-mRNA provides transient, safer alternatives to viral vector-based approaches and facilitates emerging strategies such as in vivo CAR programming and IVT-mRNA vaccine-like boosters. Despite these advantages, challenges remain, including delivery precision, durability of therapeutic effects, and limited clinical trial success. Beyond therapeutic mechanisms, the integration of bioinformatics and AI in IVT-mRNA design is accelerating the development of personalized and efficient cancer treatments. Overall, mRNA technology is redefining immunotherapy in hematology and holds the potential to broaden access to advanced treatments globally.
Keywords: mRNA technology, hematologic malignancies, CAR-T cells, bispecific antibodies, monoclonalantibodies, artificial intelligence in hematology
Received: 05 Aug 2025; Accepted: 26 Sep 2025.
Copyright: © 2025 Hunia, Tomasik, Czerwik, Pezeshki and Nowis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jaromir Hunia, jaromir.hunia@wum.edu.pl
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.